(CercleFinance.com) – AstraZeneca announced Monday that a phase 2 clinical study of Tezspire, its new asthma treatment, had not met its primary endpoint in chronic obstructive pulmonary disease (COPD).
The first results of the trial show that the drug, administered by injection, only reduced the exacerbations of symptoms linked to COPD by 17% over a full year, a level considered insignificant by one point. statistical view.
The laboratory, however, highlights data considered ‘encouraging’ in patients with a blood eosinophil level greater than or equal to 150 cells/µL, a subcategory which represents 65% of patients with COPD.
In this patient population, the reduction in moderate or severe exacerbations reached 37%, a result which this time can be considered significant.
Tezspire, developed in collaboration with Amgen, is a human monoclonal antibody that inhibits a key cytokine responsible for the persistence of allergic-type respiratory inflammation.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
